Related Experiment Video
Updated: Nov 28, 2025
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
1.3K
Fibrosis: from mechanisms to medicines
Neil C Henderson1,2, Florian Rieder3,4, Thomas A Wynn5
1University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, UK.
Nature
|November 26, 2020
Summary
Fibrosis, a major cause of death, is a dynamic process, not irreversible. Research is exploring new therapeutic strategies to treat fibrotic diseases by targeting key mechanisms.
Area of Science:
- Pathobiology
- Translational Medicine
- Regenerative Medicine
Background:
- Fibrosis affects any organ, contributing to 45% of deaths in industrialized nations.
- Previously considered progressive and irreversible, fibrosis is now understood as a dynamic process.
- A significant gap exists between identifying antifibrotic targets and developing effective human treatments.
Purpose of the Study:
- To discuss experimental strategies for dissecting fibrosis mechanisms.
- To explore translational approaches for fibrosis therapies.
- To highlight the emergence of precision medicine for fibrotic diseases.
Main Methods:
- Review of preclinical models and clinical trials in various organ systems.
- Analysis of cellular and molecular mechanisms regulating fibrosis.
- Examination of translational strategies for therapeutic development.
Main Results:
- Fibrosis is a dynamic and potentially reversible process, challenging previous assumptions.
- Experimental strategies are revealing key cellular and molecular regulators of fibrosis.
- Translational approaches are paving the way for precision medicine in fibrosis treatment.
Conclusions:
- Fibrosis is a dynamic process with therapeutic potential.
- Understanding fibrosis pathobiology is crucial for developing new treatments.
- Precision medicine offers a promising future for managing fibrotic diseases.
More Related Videos
Related Concept Videos
01:24Cystic Fibrosis: Management
318
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
318
01:09Introduction to Fibroblasts
3.6K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.6K
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
332
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
332
01:29Inflammatory Bowel Disease IV: Pharmacological Management
311
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
311
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
318
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
318
01:21Drugs for Treatment of Constipation-Predominant IBS
524
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
524